Brief: OSE Immunotherapeutics: Dosing Of 1st Healthy Volunteer In Phase 1 Clinical Trial Of Its Multi-Variant Second-Generation Covid-19 Vaccine

Ose Immunotherapeutics SA

26/05/2021 06:37

May 26 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS ANNOUNCES DOSING OF THE FIRST
HEALTHY
VOLUNTEER IN  PHASE 1 CLINICAL TRIAL OF ITS MULTI-VARIANT
SECOND-GENERATION COVID-19 VACCINE
    * FIRST-IN-HUMAN STUDY EVALUATING COVEPIT, A MULTI-VARIANT T
CELL
COVID-19 VACCINE FOR PEOPLE AT RISK AND VULNERABLE POPULATIONS
    * COVEPIT IS A PEPTIDE-BASED VACCINE AIMING TO INDUCE
CD8+T-CELL-MEDIATED IMMUNE RESPONSE AGAINST 11 DIFFERENT
PROTEINS OF SARS-COV-2 VIRUS TO PROVIDE A LONG-TERM CELLULAR
IMMUNITY WITH MEMORY T CELLS
    * PHASE 1 STUDY EXPECTED TO READ-OUT IN SEPTEMBER 2021

Source text for Eikon:  ID:nGNXbyKdpj 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))